Two new compounds suppress tumor growth in cell culture and mouse xenograft models of Ewing sarcoma, a rare pediatric cancer. These 2 compounds are similar to mithramycin, also known as picamycin, a drug no longer manufactured due to its toxicity.
Combining two anti-tumor agents appears to increase the sensitivity of cancer cells to these drugs and seems to lead to more effective Ewing's sarcoma treatment.
The first reported case of endoscopic spinal tumor extraction enabled accurate diagnosis and allowed for patient reporting of sensations and motor testing.
Inhibiting the protein Sirtuin1 could play a part in fighting Ewing sarcoma, a common bone cancer in adolescents and children.
Better understanding of the two distinct processes at the heart of the genetic abnormality driving Ewing sarcoma development could lead to new, more effective therapies.
When Ewing sarcoma tumors in mice were treated with combination therapy that included drugs from a family of agents developed to fight breast cancer, the tumors disappeared in a majority of test cases.
A combination of experimental drugs caused Ewing sarcoma tumors to disappear in mice.
Ewing sarcoma is most commonly caused by the improper fusion of the gene EWS with the gene FLI1. Though the cause has long been known, therapeutic targeting of this fusion has, to date, proven difficult.
Discovery of a new drug with high potential to treat Ewing sarcoma and of the previously unknown mechanism behind the disease came hand-in-hand.
When measures are implemented to ensure that radiation protocols are followed, deviations decrease and overall survival improves in patients with cancer.
No increased toxicity with increasing chemo from every three weeks to every two weeks.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis
- GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible
- Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Metronomic Chemotherapy: Improved Tumor Blood Supply Leads to Better Treatment
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|